Investigational Studies

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]

LONDON, May 02, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 May, 2017 its second quarter financial results for the period ending 31 March, 2017. GW will also host a […]

Receive News Stock Ratings for GW Pharmaceuticals PLC- Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GW Pharmaceuticals PLC- and related stocks with our FREE daily email newsletter. … read more at: https://www.thecerbatgem.com/2017/05/05/gw-pharmaceuticals-plc-gwph-receives-new-coverage-from-analysts-at-maxim-group-updated.html

LONDON, May 02, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 May, 2017 its second quarter financial results for the period ending 31 March, 2017. GW will also host a […]

Maxim Group started coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a report released on Thursday. The brokerage issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock. “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled […]

by

LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex® (cannabidiol or CBD) […]

by

Equities researchers at Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note issued to investors on Thursday. The brokerage set a “buy” rating and a $135.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 17.64% from the stock’s current price. The […]

by

In the Phase 3 of the clinical trials conducted by GW Pharmaceuticals and the Ohio State University on the effectiveness of Epidiolex, results showed that the cannabis-based drug lowered the number of epileptic seizures experienced by children with Lennox-Gastaut syndrome by half. What Is Lennox-Gastaut Syndrome? The Lennox-Gastaut syndrome is one of the rare forms […]

by

Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note published on Thursday morning. The firm issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock. “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are […]

by